Teleflex Incorporated (TFX) Stock: Price, Forecast & Analyst Target
Teleflex Incorporated (TFX) — MoonshotScore 61/100 (Fair band), calculated Nov 18, 2026. Price $161.58 (-1.11%), as of the Nov 20, 2026 trading session; market cap $6.41B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Teleflex Incorporated · TFX · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Teleflex manufactures single-use medical devices for surgical, interventional, and critical-care settings, with a portfolio spanning vascular access catheters, interventional cardiology tools, and anesthesia equipment. The critical question is whether recent operational disruption and margin compression can be reversed, or whether the company faces structural headwinds to profitability.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Teleflex (TFX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $567M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 2.86 · Piotroski F 7
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 56 | Fair | |
| 56 | Fair | |
| 56 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $161.58 | |
| Change on the day | -1.11% | |
| 52-week range | $100.18–$161.58 | |
| Market capitalisation | $6.41B | — |
| Price / earnings (trailing) | 19.18 | |
| Shares traded on the day | 655.0K | |
| Beta (volatility vs the S&P 500) | 0.83 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Teleflex (TFX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Teleflex (TFX), and what does it report?
Short answer · as of
Teleflex's reported revenue measures the volume of single-use devices sold to hospitals, clinics, and healthcare provider networks.
Research dated 2026-09-13.
The quarterly earnings reflect both volume growth and pricing power, minus the cost of goods sold and substantial selling and distribution expenses required to reach hospital buyers across different product categories. The company operates through distinct business units—Vascular Access, Interventional Cardiology, Surgical, and Respiratory—each serving different customer sets.
What the numbers measure is the company's ability to maintain market share in markets where it competes against both large diversified device companies and nimble specialists. Gross margins reveal pricing discipline; operating margins show whether administrative costs are controlled as the company scales. The reported net result has been volatile in recent periods, reflecting both operational challenges and significant charges related to acquisitions and restructuring.
What do the latest results show for Teleflex (TFX)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $567M.
Research dated 2026-09-13.
Recent results show a company in transition, with large operating losses in the most recent fiscal year despite positive gross margins on product sales. The latest quarterly earnings improved substantially, suggesting the worst of the operational disruption may be past. However, net margins remain deeply negative on a trailing-twelve-month basis, indicating that the recovery is incomplete.
Management's outlook emphasizes margin expansion ahead, with expectations that cost reduction initiatives and operating leverage will drive profitability recovery. The company cautioned on near-term revenue growth, suggesting it is prioritizing profitable growth over volume. The strategy appears to be to streamline operations, divest lower-margin business units, and focus on core high-value products where the company has defensible positions.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $567.78M Nov 5, 2026
- Latest report · revenue estimate
- $565.52M Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $567.78M | $565.52M | $2.6300 | $1.9000 |
| Aug 6, 2026 | $570.30M | $559.59M | $1.7600 | $1.2800 |
| May 7, 2026 | $548.26M | $536.91M | $1.3900 | $1.2100 |
| Feb 26, 2026 | $569.00M | $919.31M | $1.9300 | $3.7300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $567M | -$409M | -$9.24 (diluted) |
| Q4 FY2025 | -$402M | -$714M | -$16.15 (diluted) |
| Q1 FY2026 | $548M | -$8M | -$0.18 (diluted) |
| Q2 FY2026 | $570M | $100M | $2.28 (diluted) |
What are the financial strengths and risks for Teleflex (TFX)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Teleflex carries significant debt relative to its size, with total debt substantially exceeding cash and short-term investments. The debt-to-equity ratio exceeds one, indicating the company is leveraged beyond typical manufacturing norms. Operating cash flow is positive, allowing the company to service debt and fund operations, but free cash flow is constrained by capital expenditure requirements and interest expenses.
The principal risks are near-term: if operational improvements do not materialize, the leverage position becomes dangerous. The company is also exposed to hospital consolidation and pricing pressure, as healthcare systems increasingly demand volume discounts. A recession in elective procedures would reduce demand immediately. Long-term, the business is sound, but the next quarters will determine whether the company successfully executes its turnaround or faces a credit downgrade.
What should you watch next at Teleflex (TFX)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-13.
Watch for quarterly operating margin trends and management's disclosure of restructuring completion and annualized savings. These will signal whether the operational improvement is real or temporary. Monitor revenue growth rates by segment, as a slowdown in Vascular Access—the largest segment—would undermine the turnaround narrative.
Track the company's debt refinancing activity and whether management provides updated profitability targets. Analyst sentiment and rating agency commentary will reveal whether the financial community believes the turnaround is credible. Hospital capital spending and elective procedure volumes are leading indicators of Teleflex's demand environment—weakness there would validate near-term caution on the company's prospects.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Teleflex compare with its peers?
Short answer
Teleflex's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Teleflex differs from competitors through its breadth—it operates across multiple distinct device categories, which provides customer relationships that specialists lack. The company sells into hospital surgical suites, interventional cardiology labs, and critical-care units, creating touchpoints that allow cross-selling. However, this breadth also creates complexity and redundancy in operations compared with focused competitors.
The company's competitive position varies by product line. In Vascular Access, it maintains a strong position with the Arrow brand. In Interventional Cardiology, it competes against larger diversified players with deeper pockets. The Surgical and Respiratory divisions face similar dynamics. The strength of Teleflex relative to both pure diversified device companies and specialist operators remains unproven in this turnaround phase—execution will determine whether the broad portfolio is an advantage or a liability.
| Company | Price | Market value | Score |
|---|---|---|---|
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $120.16 Nov 20, 2026 | $5.47B | 83 5-pillar Nov 18, 2026 | |
| $84.34 Nov 20, 2026 | $5.05B | 81 5-pillar Nov 18, 2026 | |
| $140.08 Nov 20, 2026 | $8.88B | 77 5-pillar Nov 18, 2026 | |
| $172.52 Nov 20, 2026 | $4.31B | 73 5-pillar Nov 18, 2026 | |
| $15.65 Nov 20, 2026 | $4.27B | 73 5-pillar Nov 18, 2026 | |
| $14.84 Nov 20, 2026 | $10.1B | 71 5-pillar Nov 18, 2026 | |
| $163.81 Nov 20, 2026 | $10.5B | 71 5-pillar Nov 18, 2026 | |
| Teleflex (TFX) — this page | $161.58 | $6.41B | 61 |
| $55.39 Nov 20, 2026 | $8.77B | 51 5-pillar Nov 18, 2026 | |
| $58.88 Nov 20, 2026 | $11.2B | 40 5-pillar Nov 18, 2026 | |
| $44.94 Nov 20, 2026 | $7.55B | 35 5-pillar Nov 18, 2026 | |
| $20.69 Nov 19, 2026 | $7.40B | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $158.00 – $170.00
- Consensus target
- $162.33
- Median target
- $160.00
Consensus record · Captured .
Measured against a quoted price of $161.58 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 8
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TFX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Baupost Group | Seth Klarman | Q3 2026 | 0% | $0 | Sold out (was $178.60M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Teleflex (TFX)?
TFX Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is the Arrow brand and why is it important to Teleflex?
Arrow is a recognized brand of vascular access catheters and related devices used in critical care and surgery. It represents decades of market share and clinical preference. The Arrow brand generates the largest share of Teleflex revenue and anchors customer relationships, making it the company's most defensible asset.
Why did Teleflex's profitability collapse so suddenly?
The company acquired Artis Medical and Vascular Solutions, integrating them while simultaneously dealing with supply chain disruption and manufacturing challenges. Integration costs, purchase accounting adjustments, and operational missteps created large losses. Additionally, hospitals reduced elective procedures, pressuring demand.
What is the UroLift System and what market does it serve?
UroLift is an implantable device for treating lower urinary tract symptoms from benign prostatic hyperplasia—enlarged prostate in aging men. It offers a less invasive alternative to surgical removal, creating a recurring revenue stream as the population ages. The device represents a higher-margin business within the company's portfolio.
Does Teleflex's turnaround depend on acquiring or divesting units?
Management has signaled focus on core, profitable product lines and has divested or is evaluating divestiture of lower-margin assets. The turnaround strategy appears to emphasize operational excellence in existing units rather than additional acquisitions, marking a shift from the growth-by-acquisition approach that created recent challenges.
What is the TFX stock price today?
The last price recorded for Teleflex Incorporated (TFX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TFX price target?
The analyst consensus price target for Teleflex Incorporated (TFX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 38 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com